Metagenomic next-generation sequencing improves pathogen detection in culture-negative infections: a diagnostic performance study
- 1King Faisal Specialist Hospital and Research Centre
- 2Alfaisal University College of Medicine
Abstract
The conventional microbiological diagnosis is frequently insensitive, time consuming and targeted. Patients with underlying immune suppression and those who have recently been on antibiotics often have culture-negative infections. In recent years, metagenomic next-generation sequencing (mNGS) has emerged as a novel, pathogen-agnostic diagnostic approach. A total of 136 clinical specimens were submitted for metagenomic next-generation sequencing (mNGS) between August 2022 and January 2024. Of these samples, 86 from 73 patients were included in this retrospective study. Thirteen patients had more than one specimen included in the study. All specimens were processed using conventional microbiological methods and analyzed using mNGS technology, either by using Illumina next-generation sequencing technology or Oxford Nanopore long-read technology. The diagnostic performance characteristics, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated for both methods. The agreement between the two methods was evaluated using Cohen’s kappa coefficient. The paired comparisons were made using the McNemar test. The areas under the ROC curves for both methods were calculated, and the multivariable logistic regression analysis was used to identify the variables that were independently associated with mNGS positivity. Here, conventional microbiology identified pathogens in 16.3% of samples, whereas mNGS identified pathogens in 45.3% of samples. The sensitivity and specificity of mNGS were 57.1 and 84.2%, respectively. By McNemar testing, there was significant detection of pathogens by mNGS ( p = 0.0015). The agreement between two methods was poor (kappa = 0.20). The ROC curve for mNGS results showed moderate diagnostic accuracy with an AUC of 0.71. By multivariable logistic regression, immunocompromised status (OR 2.8, 95% CI 1.3–6.0, p = 0.018) and positive imaging findings (OR 3.1, 95% CI 1.4–6.9, p = 0.010) were independently associated with mNGS positivity. mNGS is able to identify more pathogens in culture-negative cases than conventional methods. There is scope for mNGS to be used in a complementary fashion, whilst relying on conventional methods as the primary tool for diagnosis of infections. Notably, the greatest additional information will come from the use of mNGS in immunocompromised patients.
Related
- Cerebrospinal fluid metagenomic next-generation sequencing for culture-negative anaerobic central nervous system infection involving Prevotella oris: attribution challenges in low-biomass specimens
- High-throughput screening for central nervous system infection-associated pathogens using TaqMan array cards, metagenomic next-generation sequencing, and targeted next-generation sequencing: a retrospective study
- Metagenomic next-generation sequencing of aqueous humor guides targeted therapy for Staphylococcus epidermidis endophthalmitis in chronic ocular graft-versus-host disease: a case report
- Targeted next-generation sequencing: a promising approach for pathogen and antimicrobial resistance gene detection in urinary tract infections
- Large-scale metagenomic characterization of the vaginal microbiome and uropathogens in women with recent bacterial vaginosis and urinary tract infections
BibTeX
@article{tayeb2026metagenomic,
title = {{Metagenomic next-generation sequencing improves pathogen detection in culture-negative infections: a diagnostic performance study}},
author = {Hamsa T. Tayeb and Mohamed Abouelhoda and Abdulmohsen Alqasabi and Amna Magrashi and Ghada Nafe and Turki Alzahrani and Suzan Alzeer and Razan Bakheet},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1971380},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1971380/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metagenomic next-generation sequencing improves pathogen detection in culture-negative infections: a diagnostic performance study
AU - Hamsa T. Tayeb
AU - Mohamed Abouelhoda
AU - Abdulmohsen Alqasabi
AU - Amna Magrashi
AU - Ghada Nafe
AU - Turki Alzahrani
AU - Suzan Alzeer
AU - Razan Bakheet
PY - 2026
DA - 2026/10/28
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1971380
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1971380/full
AB - The conventional microbiological diagnosis is frequently insensitive, time consuming and targeted. Patients with underlying immune suppression and those who have recently been on antibiotics often have culture-negative infections. In recent years, metagenomic next-generation sequencing (mNGS) has emerged as a novel, pathogen-agnostic diagnostic approach. A total of 136 clinical specimens were submitted for metagenomic next-generation sequencing (mNGS) between August 2022 and January 2024. Of these samples, 86 from 73 patients were included in this retrospective study. Thirteen patients had more than one specimen included in the study. All specimens were processed using conventional microbiological methods and analyzed using mNGS technology, either by using Illumina next-generation sequencing technology or Oxford Nanopore long-read technology. The diagnostic performance characteristics, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated for both methods. The agreement between the two methods was evaluated using Cohen’s kappa coefficient. The paired comparisons were made using the McNemar test. The areas under the ROC curves for both methods were calculated, and the multivariable logistic regression analysis was used to identify the variables that were independently associated with mNGS positivity. Here, conventional microbiology identified pathogens in 16.3% of samples, whereas mNGS identified pathogens in 45.3% of samples. The sensitivity and specificity of mNGS were 57.1 and 84.2%, respectively. By McNemar testing, there was significant detection of pathogens by mNGS ( p = 0.0015). The agreement between two methods was poor (kappa = 0.20). The ROC curve for mNGS results showed moderate diagnostic accuracy with an AUC of 0.71. By multivariable logistic regression, immunocompromised status (OR 2.8, 95% CI 1.3–6.0, p = 0.018) and positive imaging findings (OR 3.1, 95% CI 1.4–6.9, p = 0.010) were independently associated with mNGS positivity. mNGS is able to identify more pathogens in culture-negative cases than conventional methods. There is scope for mNGS to be used in a complementary fashion, whilst relying on conventional methods as the primary tool for diagnosis of infections. Notably, the greatest additional information will come from the use of mNGS in immunocompromised patients.
SN - 1664-302X
ER -